Anthropic IPO Filing, Steady Crude Prices Energize Asian Stock Markets

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

COLL vs. DSNKY: Which Stock Is the Better Value Option?

AstraZeneca inks AI drug discovery deal worth up to $1.5B with insitro

Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

Will there be more to Daiichi’s story than DXd ADCs?

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration

Sector Update: Healthcare Stocks Steady Late Afternoon

AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3

AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact

AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo

Daiichi Sankyo Co Ltd's Dividend Analysis